CHF 36.12
(0.94%)
Year | Eps | Eps Growth |
---|---|---|
2023 | 0.18 USD | -91.76% |
2022 | 1.82 USD | -5.21% |
2021 | 1.92 USD | 102.11% |
2020 | 0.95 USD | 0.0% |
Year | Eps | Eps Growth |
---|---|---|
2024 Q1 | 0.17 USD | 213.33% |
2024 Q2 | 0.17 USD | 0.0% |
2023 Q3 | -0.18 USD | -175.0% |
2023 Q1 | 0.25 USD | -43.18% |
2023 FY | - USD | -91.76% |
2023 Q2 | 0.24 USD | -4.0% |
2023 Q4 | -0.15 USD | 16.67% |
2022 Q1 | 0.50 USD | 0.0% |
2022 FY | - USD | -5.21% |
2022 Q4 | 0.44 USD | 2.33% |
2022 Q3 | 0.43 USD | -17.31% |
2022 Q2 | 0.52 USD | 4.0% |
2021 FY | - USD | 102.11% |
2020 FY | - USD | 0.0% |
Name | Eps | Eps Difference |
---|---|---|
Relief Therapeutics Holding AG | -8.35 CHF | 102.156% |
Tecan Group AG | 10.34 CHF | 98.259% |
Santhera Pharmaceuticals Holding AG | 5.18 CHF | 96.525% |
Basilea Pharmaceutica AG | 0.87 CHF | 79.31% |
Bachem Holding AG | 1.50 CHF | 88.0% |
Siegfried Holding AG | 26.61 CHF | 99.324% |
Molecular Partners AG | -1.89 CHF | 109.524% |